Skip to main content

Table 1 Serum tumor markers in bilharzial and non-bilharzial bladder cancer patients compared to normal (unaffected) patients

From: Levels of certain tumor markers as differential factors between bilharzial and non-biharzial bladder cancer among Egyptian patients

Parameters

Control

Bilharzial bladder

cancer patients

non-bilharzial

bladder cancer

patients

ANOVA

P <

1. XO (μmol uric acid/min/ml)

LSD

0.3 ± 0.05

(2,3)

2.77 ± 0.33

(1,3)

1.58 ± 0.23

(1,2)

P < 0.0001

2. Fructosamine (μmol/L)

LSD

337.88 ± 34.4

(2,3)

1145.27 ± 146.16

(1,3)

742.3 ± 132.44

(1,2)

P < 0.0001

3. hydroxylproline (μg/ml)

LSD

23.35 ± 2.83

(2,3)

78.56 ± 10.48

(1,3)

46.06 ± 4.28

(1,2)

P < 0.0001

4. IgE (IU/ml)

LSD

44.37 ± 1.66

(2,3)

301.49 ± 14.04

(1,3)

269.0 ± 7.66

(1,2)

P < 0.0001

5. TNF- (Pg/ml)

LSD

7.8 ± 0.22

(2,3)

37.7 ± 1.61

(1,3)

24.6 ± 0.84

(1,2)

P < 0.0001

  1. Data are represented as mean ± SD of 10 control and 30 patients (15 patients bilharzial and 15 non-bilharzial)